Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy. Results of their study were published in the Journal for Immunotherapy of Cancer.
TIL therapy starts with doctor’s removing tumors from the patient. These tumors are sent to a lab, where they are dissected to collect immune cells that have infiltrated the tumor, known as tumor-infiltrating lymphocytes (TILs). These TILs are then grown in large quantities and reinfused into the patient’s body to seek out and attack cancer cells. While it’s already FDA-approved for melanoma, new Moffitt research shows that a simple tweak in the lab could make it work even better…